

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0163US1	Application No. 10/582,176
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Kiyotaka Nakano <i>et al.</i>	
		Filing Date April 18, 2007	Group Art Unit 1641

U.S. Patent Documents							
Examiner Initial	Desig. ID	Document Number	Publication Date	Patentee	Class	Subclass	Filing Date If Appropriate
/P.D./	1	4,946,778	08/07/1990	Ladner <i>et al.</i>			
/P.D./	2	5,789,554	08/04/1998	Leung <i>et al.</i>			
/P.D./	3	7,456,260	11/25/2008	Rybak <i>et al.</i>			
/P.D./	4	2008/0248037	10/09/2008	Li <i>et al.</i>			
/P.D./	5	2009/0117097	05/07/2009	Igawa <i>et al.</i>			

Foreign Patent Documents or Published Foreign Patent Applications								
Examiner Initial	Desig. ID	Document Number	Publication Date	Country or Patent Office	Class	Subclass	Translation	
							Yes	No
/P.D./	6	WO 99/12973	03/18/1999	WIPO			English abstract	
/P.D./	7	WO 01/87337	11/22/2001	WIPO				
/P.D./	8	WO 2004/003019	01/08/2004	WIPO				

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
/P.D./	9	ARNDT <i>et al.</i> , "Factors Influencing the Dimer to Monomer Transition of an Antibody Single-Chain Fv Fragment," <i>Biochemistry</i> , 37:12918-12926 (1998)
/P.D./	10	DUFNER <i>et al.</i> , "Harnessing phage and ribosome display for antibody optimization," <i>Trends Biotechnol.</i> , 24(11):523-529 (2006)
/P.D./	11	ICHIKAWA <i>et al.</i> , "Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte cytotoxicity," <i>Nat. Med.</i> , 7:954-960 (2001)
/P.D./	12	KUMAR <i>et al.</i> , "Molecular cloning and expression of the Fabs of human autoantibodies in <i>Escherichia coli</i> ," <i>The Journal of Biological Chemistry</i> , 275(41):35129-35136 (2000)
/P.D./	13	MATEO <i>et al.</i> , "CD47 ligation induces caspase-independent cell death in chronic lymphocytic leukemia," <i>Nat. Med.</i> , 5(11):1277-1284 (1999)
/P.D./	14	PAUL, <i>Fundamental Immunology</i> , 3rd Edition, Raven Press, NY, Chapter 8, pp. 292-295 (1993)
/P.D./	15	SMITH-GILL <i>et al.</i> , "Contributions of immunoglobulin heavy and light chains to antibody specificity for lysozyme and two haptens," <i>The Journal of Immunology</i> , 139:4135-4144 (1987)
/P.D./	16	SONG <i>et al.</i> , "Light chain of natural antibody plays a dominant role in protein antigen binding," <i>Biochemical and Biophysical Research Communications</i> , 268:390-394 (2000)
/P.D./	17	WAKELEE <i>et al.</i> , "Phase I and pharmacokinetic study of lexatumumab (HGS-ETR2) given every 2 weeks in patients with advanced solid tumors," <i>Ann. Oncol.</i> On-line publication (7/24/2009)
/P.D./	18	WARD <i>et al.</i> , "Binding activities of a repertoire of single immunoglobulin variable domains secreted from <i>Escherichia coli</i> ," <i>Nature</i> , 341:544-546 (1989)
/P.D./	19	WHITLOW <i>et al.</i> , "Multivalent Fvs: characterization of single-chain Fv oligomers and preparation of a bispecific Fv," <i>Protein Eng.</i> , 7(8):1017-1026 (1994)

Examiner Signature /Pensee Do/	Date Considered 01/15/2010
-----------------------------------	-------------------------------

EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

Substitute Form PTO-1449 (Modified)	U.S. Department of Commerce Patent and Trademark Office	Attorney Docket No. 14875-0163US1	Application No. 10/582,176
Information Disclosure Statement by Applicant (Use several sheets if necessary) (37 CFR §1.98(b))		Applicant Kiyotaka Nakano <i>et al.</i>	
		Filing Date April 18, 2007	Group Art Unit 1641

Other Documents (include Author, Title, Date, and Place of Publication)		
Examiner Initial	Desig. ID	Document
/P.D./	20	YAGITA <i>et al.</i> , "TRAIL and its receptors as targets for cancer therapy," <i>Cancer Sci.</i> , 95:777-783 (2004)
/P.D./	21	FISH & RICHARDSON P.C., Amendment in Reply to Action dated March 16, 2009 in U.S. App. Ser. No. 10/550,934, filed September 10, 2009, 75 pages
/P.D./	22	FISH & RICHARDSON P.C., Response to Restriction Requirement dated July 8, 2009 in U.S. App. Ser. No. 11/913,229, filed August 4, 2009, 1 page
/P.D./	23	U.S. EXAMINER ANNE GUSSOW, USPTO Non-Final Office Action in U.S. App. Ser. No. 10/582,304, mailed September 15, 2009, 22 pages
/P.D./	24	EPO EXAMINER TERESA SOMMERFELD, European Search Report for App. Ser. No. EP 06 74 6578, dated June 25, 2009, 2 pages
/P.D./	25	FISH & RICHARDSON P.C., Amendment in Reply to Action dated April 15, 2009 in U.S. App. Ser. No. 10/551,504, filed August 14, 2009, 19 pages
/P.D./	26	KLARQUIST SPARKMAN, LLP Response to Restriction Requirement dated May 26, 2009 in U.S. App. Ser. No. 10/582,654, filed June 23, 2009, 2 pages
/P.D./	27	U.S. EXAMINER LYNN ANNE BRISTOL, USPTO Office Action in U.S. App. Ser. No. 10/582,654, mailed September 1, 2009, 36 pages
/P.D./	28	U.S. EXAMINER DAVID J. BLANCHARD, USPTO Final Office Action in U.S. App. Ser. No. 10/399,518, mailed September 11, 2009, 24 pages
/P.D./	29	U.S. EXAMINER LYNN ANNE BRISTOL, USPTO Restriction Requirement in U.S. App. Ser. No. 10/257,864, mailed February 1, 2006, 14 pages

Examiner Signature /Pensee Do/	Date Considered 01/15/2010
EXAMINER: Initials citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	